Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: The African-American Study of Kidney Disease and Hypertension pilot study

American Journal of Kidney Diseases

Volumn 29, Issue 5, 1997, Pages 720-728

  Hall, W Dallas ^a,b   Kusek, John W ^a   Kirk, Katharine A ^a   Appel, Lawrence J ^a   Schulman, Gerald ^a   Agodoa, Lawrence Y ^a   Glassock, Richard ^a   Grim, Clarence ^a   Randall, Otelio S ^a   Massry, Shaul G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blacks; blood pressure; hypertensive nephrosclerosis; Renal function

Indexed keywords

AMLODIPINE; ATENOLOL; ENALAPRIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NEPHROSCLEROSIS;

EID: 12644301198     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90125-6     Document Type: Article

References (38)

1. Gillum RF: Cardiovascular disease in the United States: An epidemiologic overview, in Saunders E (ed): Cardiovascular Diseases in Blacks. Philadelphia, PA, Davis, 1991, pp 3-16
2. Eisner GM: Hypertension: Racial differences. Am J Kidney Dis 16:35-40, 1990
3. US Renal Data System: USRDS 1995 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, p B41 (appendix)
4. Jones CA, Agodoa L: Kidney disease and hypertension in blacks: Scope of the problem. Am J Kidney Dis 4:6-9, 1993 (suppl 1)
5. Whelton PK, Klag MJ: Hypertension as a risk factor for renal disease. Review of clinical and epidemiological evidence. Hypertension 13:19-27, 1989, (suppl I)
6. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan H: Renal insufficiency in treated essential hypertension. N Engl J Med 320:684-688, 1989
7. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA, for HDFP: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension 13:80-93, 1989 (suppl I)
8. Rosansky SJ, Hoover DR, King L, Gibson J: The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 150:2073-2076, 1990
9. National high blood pressure education program working group report on hypertension and chronic renal failure. Arch Intern Med 151:1280-1287, 1991
10. Flack JM, Neaton JD, Daniels B, Esunge P: Ethnicity and renal disease: Lessons learned from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis 21:31-40, 1993 (suppl 1)
11. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE: Early predictors of 15 year end-stage renal disease in hypertensive patients. Hypertension 25:587-594, 1995
12. Madhaven S, Stockwell D, Cohen H, Alderman MH: Renal function during antihypertensive treatment. Lancet 345:749-751, 1995
13. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155:1073-1080, 1995
14. Toto RD, Mitchell HC, Smith RD, Lee H-C, McIntire D, Pettinger WA: "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48:851-859, 1995
15. Pedersen EB, Mogensen CF: Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate, and renal plasma flow rate in patients with essential hypertension. Scand J Clin Lab Invest 36:231-237, 1976
16. Bauer JH, Reams GP: Renal protection in essential hypertension: How do angiotensin-converting enzyme inhibitors compare with calcium antagonists? J Am Soc Nephrol 1:80-87, 1990 (suppl 2)
17. Zuccelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
18. Epstein M: Calcium antagonists and renal protection. Current status and future perspectives. Arch Intern Med 152:1573-1584, 1992
19. ter Wee PM, Micheli AG, Epstein M: Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med 154:1185-1202, 1994
20. Keane WT, Anderson S, Aurell M, de Zeeuw D, Narins RG, Povar G: Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Intern Med 111:503-516, 1989
21. Mimran A, Ribstein J: Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal disease. Am J Hypertens 7:73S-81S, 1994 (suppl)
22. Ritz E: Are antihypertensive drugs similar in protecting the kidney? Am J Hypertens 8:53S-58S, 1995 (suppl)
23. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
24. Himmelmann A, Hansson L, Hansson B-G, Hedstrand H, Skogstrom K, Ohrvik J, Furangen A: ACE inhibition preserves renal function better than β-blockade in the treatment of essential hypertension. Blood Press 4:85-90, 1995
25. Wright JT Jr, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R, for the AASK Pilot Study Investigators: Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 17:3S-16S, 1996 (suppl 4)
26. Whelton PK, Lee JY, Kusek JW, Charleston J, DeBruge J, Douglas M, Faulkner M, Greene PG, Jones CA, Keefer S, Kirk KA, Levell B, Norris K, Peng SN, Powers SN, Retta TM, Smith DE, Ward H, for the AASK Pilot Study Investigators: Recruitment experience in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 17:17S-35S, 1996 (suppl 4)
27. Breyer JA, Toto RD, Hall WD, Norris KC, Massry SG, for the AASK Pilot Investigators: Baseline characteristics of patients entering the pilot African-American Study of Kidney Disease (Pilot-AASK). J Am Soc Nephrol 5:557, 1994 (abstr)
28. 169Yb-DTPA, and inulin. Am J Kidney Dis 16:224-235, 1990
29. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R, and the AASK Pilot Investigators: Accuracy of the diagnosis of hypertensive nephrosclerosis in African-Americans: A report from the African-American Study of Kidney Disease (AASK) trial. Kidney Int 51:244-252, 1997
30. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, Morgenstern BZ: Human blood pressure determination by sphygmomanometry. Circulation 88:2460-2470, 1993
31. Lee JY, Greene PG, Douglas M, Grim C, Kirk KA, Kusek JW, Milligan S, Smith DE, Whelton PK, for the AASK Pilot Study Investigators: Appointment attendance, pill counts, and achievement of goal blood pressure in the African American Study of Kidney Disease and Hypertension pilot study. Control Clin Trials 17:34S-39S, 1996 (suppl 4)
32. Laird NM, Ware JH: Random effects models for longitudinal data. Biometrics 38:963-974, 1982
33. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, for MDRD: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
34. Herbert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, Breyer JA, Faubert P, Rolin H, Wang S: Effect of blood pressure control on progressive renal disease in blacks and whites. Hypertension (in press)
35. Levey AS, Beck GJ, Bosch JP, Caggiula AW, Greene T, Hunsicker LG, Klahr S: Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 7:2097-2109, 1996
36. Toto R, Mitchell H, Lee H, Milan C, Pettinger W: Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 115:513-519, 1991
37. Toto RD: Angiotensin converting enzyme inhibitors and the kidney: Clinical physiology, therapeutic applications and nephrotoxicity. AKF Nephrol Lett 10:41-52, 1993
38. Grim CE: Renin and aldosterone in hypertensive blacks. J Clin Hypertens 3:43s-46s, 1987 (suppl)